Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma.
Aged
Aged, 80 and over
Antihypertensive Agents
/ administration & dosage
Female
Follow-Up Studies
Glaucoma Drainage Implants
Glaucoma, Open-Angle
/ physiopathology
Humans
Intraocular Pressure
/ drug effects
Male
Middle Aged
Prosthesis Implantation
Retrospective Studies
Stents
Tonometry, Ocular
Treatment Outcome
Visual Acuity
/ physiology
Visual Field Tests
Visual Fields
/ physiology
MIGS
Primary open-angle Glaucoma
Trabeculectomy
XEN
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
24
06
2020
accepted:
14
12
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
9
1
2021
Statut:
epublish
Résumé
The aim of this retrospective study was to compare the efficacy and safety profile of a single XEN-microstent in different types of primary and secondary open angle glaucoma. A single XEN microstent was implanted in patients with primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG), pseudoexfoliation glaucoma (PEX) and secondary glaucoma (Sec.Gl). The intraocular pressure (IOP), the active substances of the applied IOP-lowering drugs, the best corrected visual acuity (BCVA) and the mean deviation (MD) of the perimetry were measured at baseline and at regular follow-ups, scheduled at 2 days and 1, 3, 6 and 12 months after surgery. 153 eyes were included in this analysis. 113 eyes were affected by POAG (74%), 5 eyes by NTG (3%), 22 eyes by PEX (14%) and 13 eyes by Sec. Gl (9%). Mean IOP decreased in all treatment groups during the 12 months of follow-up (complete group: 23.9 ± 7.4 to 15.4 ± 5.1 mmHg (p < 0.01); POAG: 22.8 ± 6.5 to 15.1 ± 4.6 mmHg (p < 0.01); NTG: 16.6 ± 3.4 to 11.6 ± 2.2 mmHg (p < 0.05); PEX: 28.0 ± 7.9 to 17.1 ± 6.6 mmHg (p < 0.01); Sec.Gl: 28.9 ± 13.9 to 15.5 ± 6.9 mmHg (p < 0.05)). In the 153 eyes the average number of IOP-lowering drugs applied decreased from 2.6 ± 1.2 to 0.8 ± 1.3 12 months after surgery (p < 0.01). BCVA and mean deviation of automated standard perimetry remained stable in all groups during follow-up. As in eyes suffering from POAG, IOP and number of IOP-lowering drugs applied can be effectively reduced by XEN implantation in eyes suffering from NTG, PEX and secondary glaucoma while leaving BCVA and visual field unchanged. Trial was registered at DRKS (registration number: DRKS00020800 , Registered 25.February 2020 - Retrospectively registered).
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this retrospective study was to compare the efficacy and safety profile of a single XEN-microstent in different types of primary and secondary open angle glaucoma.
METHODS
METHODS
A single XEN microstent was implanted in patients with primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG), pseudoexfoliation glaucoma (PEX) and secondary glaucoma (Sec.Gl). The intraocular pressure (IOP), the active substances of the applied IOP-lowering drugs, the best corrected visual acuity (BCVA) and the mean deviation (MD) of the perimetry were measured at baseline and at regular follow-ups, scheduled at 2 days and 1, 3, 6 and 12 months after surgery.
RESULTS
RESULTS
153 eyes were included in this analysis. 113 eyes were affected by POAG (74%), 5 eyes by NTG (3%), 22 eyes by PEX (14%) and 13 eyes by Sec. Gl (9%). Mean IOP decreased in all treatment groups during the 12 months of follow-up (complete group: 23.9 ± 7.4 to 15.4 ± 5.1 mmHg (p < 0.01); POAG: 22.8 ± 6.5 to 15.1 ± 4.6 mmHg (p < 0.01); NTG: 16.6 ± 3.4 to 11.6 ± 2.2 mmHg (p < 0.05); PEX: 28.0 ± 7.9 to 17.1 ± 6.6 mmHg (p < 0.01); Sec.Gl: 28.9 ± 13.9 to 15.5 ± 6.9 mmHg (p < 0.05)). In the 153 eyes the average number of IOP-lowering drugs applied decreased from 2.6 ± 1.2 to 0.8 ± 1.3 12 months after surgery (p < 0.01). BCVA and mean deviation of automated standard perimetry remained stable in all groups during follow-up.
CONCLUSION
CONCLUSIONS
As in eyes suffering from POAG, IOP and number of IOP-lowering drugs applied can be effectively reduced by XEN implantation in eyes suffering from NTG, PEX and secondary glaucoma while leaving BCVA and visual field unchanged.
TRIAL REGISTRATION
BACKGROUND
Trial was registered at DRKS (registration number: DRKS00020800 , Registered 25.February 2020 - Retrospectively registered).
Identifiants
pubmed: 33334311
doi: 10.1186/s12886-020-01764-8
pii: 10.1186/s12886-020-01764-8
pmc: PMC7745382
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
490Références
Eye (Lond). 2018 Feb;32(2):324-332
pubmed: 28862254
Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):765-771
pubmed: 29356886
Clin Ophthalmol. 2020 Jun 30;14:1805-1832
pubmed: 32636610
Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):983-996
pubmed: 30758653
Am J Ophthalmol. 2015 Jun;159(6):1082-91
pubmed: 25748577
J Cataract Refract Surg. 2015 Sep;41(9):1905-9
pubmed: 26482822
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4789-95
pubmed: 26218906
Ophthalmologe. 2001 Jul;98(7):629-34
pubmed: 11490740
Eye (Lond). 2019 Mar;33(3):469-477
pubmed: 30356133
J Ophthalmol. 2017;2017:5457246
pubmed: 28348884
Am J Ophthalmol. 2017 Nov;183:25-36
pubmed: 28784554
Br J Ophthalmol. 1996 May;80(5):389-93
pubmed: 8695555
Ophthalmologe. 1998 May;95(5):W380-7
pubmed: 9643029
Prog Brain Res. 2015;220:37-57
pubmed: 26497784
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
Ophthalmology. 2017 Nov;124(11):1579-1588
pubmed: 28601250
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
Eye (Lond). 2002 May;16(3):297-303
pubmed: 12032721
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2707-2715
pubmed: 31494710
Ophthalmology. 1999 Oct;106(10):2010-5
pubmed: 10519600
Ophthalmology. 2012 Apr;119(4):694-702
pubmed: 22196977
J Glaucoma. 2018 Feb;27(2):140-147
pubmed: 29271806
Am J Ophthalmol. 2013 Apr;155(4):674-680, 680.e1
pubmed: 23246272
Ophthalmology. 2008 Jan;115(1):85-93
pubmed: 17629563
J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77
pubmed: 25587905
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Clin Exp Ophthalmol. 2019 Jul;47(5):581-587
pubmed: 30578661
Optom Vis Sci. 2011 Jan;88(1):E39-47
pubmed: 21131879
J Cataract Refract Surg. 2020 Mar;46(3):441-450
pubmed: 32142041
Aust N Z J Ophthalmol. 1995 May;23(2):85-91
pubmed: 7546696
PLoS One. 2017 Aug 29;12(8):e0183142
pubmed: 28850575
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
Sci Rep. 2020 Nov 9;10(1):19337
pubmed: 33168873
Arch Ophthalmol. 2002 Oct;120(10):1268-79
pubmed: 12365904